SAGE Therapeutics (SAGE) 'Hits It Out of the Park' with SAGE-217 Data - Cowen

Cowen analyst Ritu Baral reiterated an Outperform rating and $207 price target on Sage Therapeutics (NASDAQ: SAGE) after the company reported highly positive top-line data from the Ph3 ROBIN study of SAGE-217 in postpartum depression.

Baral commented, "The trial met primary endpoint with impressive, rapid, durable effect, stat sig from ~3 days through week 4 with good safety. The results were in line with our very high expectations, and the good safety profile should give comfort on ‘217’s commercial potential in MDD as well."

For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.

Shares of Sage Therapeutics closed at $97.51 yesterday.

You May Also Be Interested In

• TD Cowen Reiterates Buy Rating on Tesla (TSLA), well-positioned to scale in US AV market
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)
• New Street Research Upgrades Micron Technology (MU) to Buy